MannKind Corporation (MNKD) said on Wednesday that it has entered into up to $500 million strategic financing agreement with ...

MannKind (NASDAQ:MNKD) shares fell on Wednesday after the company reported second quarter revenue and adjusted profit below ...

MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most si ...

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung ...

Analysts anticipate MannKind to report an earnings per share (EPS) of $0.06. The announcement from MannKind is eagerly ...

MannKind Corporation (NASDAQ:MNKD) is one of the penny stocks that will skyrocket. On July 16, H.C. Wainwright assumed coverage of the stock with a ‘Buy’ rating and a $9 price target. The bullish ...

MannKind Corporation (NASDAQ: MNKD) is one of the best biotech penny stocks to buy right now. Analyst Yun Zhong from Wedbush ...

MannKind (MNKD) reported $70.08 million in revenue for the quarter ended September 2024, representing a year-over-year increase of 36.7%. EPS of $0.04 for the same period compares to $0.02 a year ago.